痴呆
帕金森病
认知障碍
内科学
生物标志物
疾病
医学
肿瘤科
心理学
阿尔茨海默病
认知功能衰退
胃肠病学
生物
生物化学
作者
Thomas J. Montine,Min Shi,Joseph F. Quinn,Elaine R. Peskind,Suzanne Craft,Carmen Ginghina,Kathryn A. Chung,Hojoong Kim,Douglas Galasko,Joseph Jankovic,Cyrus P. Zabetian,James B. Leverenz,Jing Zhang
摘要
We tested the hypothesis that the CSF biomarker signature associated with Alzheimer's disease (AD) is present in a subset of individuals with Parkinson's disease and Dementia (PD-D) or with PD and Cognitive Impairment, Not Dementia (PD-CIND). We quantified CSF Aβ(42), total tau (T-tau), and phospho-tau (P181-tau) using commercially available kits. Samples were from 345 individuals in seven groups (n): Controls ≤50 years (35), Controls >50 years (115), amnestic Mild Cognitive Impairment (aMCI) (24), AD (49), PD (49), PD-CIND (62), and PD-D (11). We observed expected changes in AD or aMCI compared with age-matched or younger controls. CSF Aβ(42) was reduced in PD-CIND (P < 0.05) and PD-D (P < 0.01), whereas average CSF T-tau and P181-tau were unchanged or decreased. One-third of PD-CIND and one-half of PD-D patients had the biomarker signature of AD. Abnormal metabolism of Aβ(42) may be a common feature of PD-CIND and PD-D.
科研通智能强力驱动
Strongly Powered by AbleSci AI